Silence Therapeutics PLC SLN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:00 PM EDT
22.33UNCH (UNCH)
Volume
1,002
Close
22.33quote price arrow up+1.19 (+5.63%)
Volume
66,857
52 week range
4.84 - 27.72
Loading...
  • Open21.20
  • Day High22.66
  • Day Low21.20
  • Prev Close21.14
  • 52 Week High27.72
  • 52 Week High Date03/14/24
  • 52 Week Low4.84
  • 52 Week Low Date07/25/23

Key Stats

  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume0.14M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change28.55

KEY STATS

  • Open21.20
  • Day High22.66
  • Day Low21.20
  • Prev Close21.14
  • 52 Week High27.72
  • 52 Week High Date03/14/24
  • 52 Week Low4.84
  • 52 Week Low Date07/25/23
  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume0.14M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change28.55

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Silence Therapeutics PLC

 

Profile

MORE
Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is developing medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver. Its wholly owned product candidates include...
Iain Ross
Non-Executive Chairman of the Board
Craig Tooman
President, Chief Executive Officer, Executive Director
Address
72 Hammersmith Road
London
W14 8TH
United Kingdom